1. Introduction {#sec1}
===============

Botulinum Toxin Type A (BoNTA) is the most effective one among the seven neurotoxins secreted by*Clostridium botulinum* \[[@B1]\]. BoNTA causes muscle relaxation and this concept nowadays is widely being used in the cosmetic treatment of wrinkles \[[@B2], [@B3]\]. In 2005 and 2008, some researchers found a face-lifting effect after intradermal injection of BoNTA to the mid and lower face \[[@B4], [@B5]\]. However, some other researchers reported that needle pricks themselves without BoNTA can make the skin become smoother as well \[[@B6]\]. In order to find out whether BoNTA can affect the human dermal fibroblasts (HDFs) directly, in 2012, Oh et al. studied the in vitro effects of BoNTA on normal HDFs and found that BoNTA has a notable effect in increasing the level of collagen production and downregulating its degradation \[[@B7]\]. Collagen is the most abundant basic element of fibrous components in the dermis and is responsible for maintaining the structural integrity of the skin by joining cells together and to the extracellular matrix (ECM) \[[@B8], [@B9]\]. These studies not only showed the positive effects of BoNTA on HDFs for remodeling skin but also implied the importance of HDFs. In 2016, Zhu et al. proved that topical BoNTA application could enhance the rejuvenation effect of fractional CO~2~ laser, further indicating that BoNTA can refine skin texture via improving the activity of HDFs \[[@B10]\]. But until now, the molecular mechanisms through which BoNTA could affect HDFs are still not completely understood.

Long noncoding RNAs (lncRNAs) are a group of noncoding RNA transcripts longer than 200 nucleotides which cannot encode proteins \[[@B11]\]. In comparison with protein-coding genes, lncRNAs have limited coding potential and show little evolutionary conservation in sequence. Furthermore, some researchers have detected that lncRNAs expression is more tissue specific and at apparently lower levels \[[@B12]\]. LncRNAs, which were previously thought to be transcriptional "noise," are now proved to have some functions by regulating gene expression at the epigenetic, transcriptional, and posttranscriptional levels and participating in some biologic functions, such as genomic imprinting, chromosome modification, intranuclear transport, transcriptional activation, and interference \[[@B13]\]. Therefore, the understanding of cellular processes in physiological conditions will not be complete without analyzing the contributions made by lncRNAs. Until now, no information is available regarding the effect of BoNTA on expression profiling of lncRNAs in HDFs.

In this study, we investigated on lncRNA expression signature together with messenger RNA (mRNA) expression profile in BoNTA treated HDFs and confirmed the changing of some differentially expressed lncRNAs and mRNA using qRT-PCR. In conjunction, we also conducted functional analysis using Gene Ontology (GO) analysis and pathway analysis, in which genes are mapped to Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways.

2. Materials and Methods {#sec2}
========================

2.1. Cell Separation and Culture {#sec2.1}
--------------------------------

Normal human skin samples were obtained from the prepuce of young healthy individuals in accordance with the ethics committee approval process of The First Affiliated Hospital of Nanjing Medical University (Nanjing, China). The acquirement of HDFs can be divided into two procedures. Initially dispase enzyme was used to separate the dermis and epidermis, and then collagenase enzyme was used to extract the HDFs. HDFs were grown in Dulbecco\'s modified Eagle medium (DMEM) with 1% penicillin-streptomycin and 10% fetal bovine serum in an environment of 5% CO~2~ at 37°C. The cells used in our study were from passages 8--11.

2.2. Group Divisions and Botulinum Toxin Type A (BoNTA) Treatment {#sec2.2}
-----------------------------------------------------------------

In order to study differentially expressed lncRNAs and mRNAs, we separated the cells into two groups, control group and BoNTA group: (1) control group: HDFs were grown in DMEM with 1% penicillin-streptomycin and 10% fetal bovine serum for 5 days and then serum-starved for 4 days, without receiving BoNTA treatment; (2) BoNTA group (48 h): HDFs were grown in DMEM with 1% penicillin-streptomycin and 10% fetal bovine serum for 5 days, serum-starved for 2 days, and then were grown in serum-free DMEM with BoNTA at a dose of 5 U/10^6^ cells for 2 days.

In order to determine whether the changes of RNAs expression in BoNTA treated HDFs were time or dosage dependent, the cells were divided into 4 groups: (1) BoNTA group (24 h): HDFs were grown in DMEM with 1% penicillin-streptomycin and 10% fetal bovine serum for 5 days, serum-starved for 2 days, and then were grown in serum-free DMEM with BoNTA at a dose of 5 U/10^6^ cells for 24 h; (2) BoNTA group (72 h): HDFs were grown in DMEM with 1% penicillin-streptomycin and 10% fetal bovine serum for 5 days, serum-starved for 2 days, and then were grown in serum-free DMEM with BoNTA at a dose of 5 U/10^6^ cells for 72 days; (3) BoNTA group (48 h 2.5 U): HDFs were grown in DMEM with 1% penicillin-streptomycin and 10% fetal bovine serum for 5 days, serum-starved for 48 h, and then were grown in serum-free DMEM with BoNTA at a dose of 2.5 U/10^6^ cells for 48 h; (4) BoNTA group (48 h 7.5 U): HDFs were grown in DMEM with 1% penicillin-streptomycin and 10% fetal bovine serum for 5 days, serum-starved for 2 days, and then were grown in serum-free DMEM with BoNTA at a dose of 7.5 U/10^6^ cells for 48 h.

All groups were rinsed with Phosphate Buffer Solution (PBS) and the medium was changed every day, except during BoNTA treatment. Each method of detection consists of these six groups of cell culture, containing about 1 × 10^7^ cells in each group, and there were at least 3 samples in each group. The BoNTA used in this study was manufactured by Lanzhou Institute of Biological Products Co., Ltd., Lanzhou, China.

2.3. Isolation of RNA and Preparation of Array Hybridization {#sec2.3}
------------------------------------------------------------

The RNA extraction was conducted using the TRIZOL reagent and then was dissolved in RNase-free water. The purified labeled genomic DNA was used for quantification and the RNA quantity was decided spectrophotometrically as A260/A280 ratio (1.9--2.1 were obtained). The collected RNAs were stored at −70°C for microarray analysis and qRT-PCR.

2.4. Microarray Analysis of lncRNAs and mRNAs Expression {#sec2.4}
--------------------------------------------------------

The Agilent Human lncRNA (8*∗*60 K) arrays were designed in this experiment for measuring the expression profiles of lncRNAs and mRNAs. The lncRNA sequences were acquired from the following databases: NCBI-RefSeq, NONCODE v4, Ensembl, broad lincRNA, and frnadb v3.4. We conducted the sample labeling, microarray hybridization, and washing according to the manufacturer\'s proposals. Briefly speaking, we initially transcribed the total RNA to double stranded cDNA, synthesized them into cRNA, and labeled them with Cyanine-3-CTP and then hybridized the labeled cRNAs onto the microarray. We applied the Agilent Scanner G2505C (Agilent Technologies) to scan the arrays after washing.

2.5. Quantitative Reverse-Transcription Polymerase Chain Reaction (qRT-PCR) {#sec2.5}
---------------------------------------------------------------------------

In order to confirm the results obtained from microarray, we applied qRT-PCR to remeasure the abundance of differentially expressed lncRNAs and mRNAs selected from microarray analysis. RNAs in the medium were determined based on the protocol of KeyGen Biotech Co., Ltd., Nanjing, Jiangsu, China. In brief, we applied TRIzol to extract the total RNAs from HDFs and then synthesized the cDNAs from the separated RNA using SuperScript III Reverse Transcriptase (KeyGen, China). QRT-PCR was performed on ABI Prism 7700 Sequence Detector (Applied Biosystems). The reactions were performed at 9°C for 10 min, then at 40 cycles at 95°C for 15 s, and followed by at 60°C for 30 s. The 2 (−ΔΔCt) methods were used to evaluate relative quantification of lncRNAs and mRNAs expression. Primer sequences of lncRNAs and mRNAs for qRT-PCR are listed in [Table 1](#tab1){ref-type="table"}. The results were expressed as mean ± SD (standard deviation) of each independent experiment.

2.6. Data Analysis {#sec2.6}
------------------

We applied the Feature Extraction software (version 10.7.1.1, Agilent Technologies) to analyze array images to get raw data and used GeneSpring (version 13.1, Agilent Technologies) to complete the fundamental analysis with the raw data. First of all, the raw data was normalized with the quantile algorithm. The probes which have signed with*P* (*p* value ≤0.05 is recommended) were selected for further data analysis. Deferentially expressed lncRNAs and protein-coding RNAs were then identified through fold change. The critical value set for up- and downregulated genes was a fold change ≥ 2.0. Afterwards, GO analysis and KEGG analysis were applied to depict alterations in the gene expression. SPSS 17.0 software (SPSS Inc., Chicago, IL, United States) was used to analyze the statistical data. The differences in RNA expression between the two groups and more than three groups were analyzed using the Student\'s*t*-test and one-way ANOVA, separately. *p* \< 0.05 was considered to indicate a statistically significant difference.

3. Results {#sec3}
==========

3.1. Different Expression Profiles of lncRNAs and mRNAs in Control Group and BoNTA Treated Group {#sec3.1}
------------------------------------------------------------------------------------------------

Data analysis showed 2124 differentially expressed lncRNAs and 638 differentially expressed mRNAs of the cells in BoNTA (48 h 5 U) treated group (fold change \> 2) compared with control group. Hierarchical clustering heat-map showed the expression ratios of mRNAs ([Figure 1(a)](#fig1){ref-type="fig"}) and lncRNAs ([Figure 1(b)](#fig1){ref-type="fig"}) between the two groups. Of the 2124 differentially expressed lncRNAs, 1122 were upregulated and 1002 were downregulated. Of the 638 differentially expressed mRNAs, 303 were upregulated and 335 were downregulated. The distinctly expressed lncRNAs are listed in [Table 2](#tab2){ref-type="table"} (fold change \> 5) and the distinctly expressed mRNAs are summarized in [Table 3](#tab3){ref-type="table"} (fold change \> 3).

3.2. QRT-PCR Analysis of lncRNAs and mRNAs Expression {#sec3.2}
-----------------------------------------------------

QRT-PCR analysis indicated the transcription of the selected lncRNAs: RP11-517C16.2-001, FR271872, LOC283352, RP11-401E9.3, FGFR3P, XXbac-BPG16N22.5, and mRNAs: collagen 19a1 (COL19A1), nitric oxide synthase 2 (NOS2), chromosome 13 open reading frame 15 (C13orf15), FBJ murine osteosarcoma viral oncogene homolog (FOS), ficolin (collagen/fibrinogen domain containing lectin) 2 (hucolin) (FCN2), serine peptidase inhibitor, Kunitz type 1 (SPINT1), placenta-specific 8 (PLAC8), E2F transcription factor 1 (E2F1), and baculoviral IAP repeat containing 5 (BIRC5), perfectly correlated to microarray results. The qRT-PCR analysis revealed that the expression level of RP11-517C16.2-001, FR271872, LOC283352, and RP11-401E9.3 in BoNTA (5 U 48 h) treated groups was upregulated to 33.479-, 39.519-, 19.713-, 26.362-, and 29.293-fold separately ([Figure 2](#fig2){ref-type="fig"}), and the expression level of FGFR3P and XXbac-BPG16N22.5 was downregulated to 2.139- and 2.554-fold, respectively ([Figure 2](#fig2){ref-type="fig"}).

For the mRNAs, in comparison with the control group, the expression level of COL19A1, NOS2, C13orf15, FOS, SPINT1, and PLAC8 was upregulated to 10.331-, 31.374-, 7.534-, 12.573-, 24.758-, and 19.885-fold in BoNTA (5 U 24 h) treated groups, respectively ([Figure 3](#fig3){ref-type="fig"}), and the expression level of FCN2, BIRC5, and E2F1 was downregulated to 1.890-, 0.923-, 0.709-fold separately ([Figure 3](#fig3){ref-type="fig"}).

3.3. GO and Pathway Analysis of Deferentially Expressed RNAs {#sec3.3}
------------------------------------------------------------

The upregulated genes were involved in 898 biological processes, 171 cellular components, and 236 molecular functions separately. The response to cell-cell signaling (−log~10~ (*p* value) = 3.7114) was the most significant term among the biological process category. The extracellular region (−log~10~ (*p* value) = 2.8128) was the most represented GO term in the cellular component category. Heparin binding (−log~10~ (*p* value) = 3.3714) was the most highly represented term within the molecular component category. The downregulated genes were involved in 880 biological processes, 179 cellular components, and 240 molecular functions, respectively. The most significant term was the response to mitotic cell cycle (−log~10~ (*p* value) = 31.3859) among the biological process category. The most represented GO term was the condensed chromosome kinetochore (−log~10~ (*p* value) = 13.0822) in the cellular component category. Heparin binding (−log~10~ (*p* value) = 6.2714) was the most highly represented term with in the molecular component category. The top ten of the number of deferentially expressed genes and the significance analyzed by GO term are demonstrated in [Figure 4](#fig4){ref-type="fig"}.

KEGG (Kyoto Encyclopedia of Genes and Genomes) was used to analyze the pathway enrichment. The pathway analysis showed that changed genes participated in the DNA replication, cell cycle, P53 signaling pathway, pathway in cancer, and melanoma. The upregulated genes participated in 157 pathways while downregulated genes participated in 169 pathways. The top ten pathways among them are shown in [Figure 5](#fig5){ref-type="fig"}.

3.4. The Regulation of BoNTA on the Expression of FGFR3P and COL19A1 {#sec3.4}
--------------------------------------------------------------------

We also performed qRT-PCR to validate the altered lncRNA expression at different time-points and different dosage of BoNTA treatment. We found that the level of FGFR3P reached the lowest at 48 h but indicated an upward trend at 72 h when treated by BoNTA at the dosage of 5 U/10^6^ cells ([Figure 6](#fig6){ref-type="fig"}). The level of FGFR3P was gradually increasing with the increasing dosage of BoNTA (at a range from 2.5 U/10^6^ cells to 7.5 U/10^6^ cells). At the same time, the level of COL19A1 in HDFs was gradually increasing with the extension of time treated by BoNTA at the dosage of 5 U/10^6^ cells ([Figure 6](#fig6){ref-type="fig"}), and its level showed a trend of increasing when the dosage of BoNTA ranges from 2.5 U/10^6^ cells to 7.5 U/10^6^ cells ([Figure 6](#fig6){ref-type="fig"}).

4. Discussion {#sec4}
=============

Recently, lncRNAs have come into the extent of probing into human biological functions and diseases \[[@B13]--[@B17]\]. Until now, only a few lncRNAs had been reported about HDFs, and studies on the expression of lncRNAs in BoNTA treated HDFs were still lacking. In this study, we identified some differentially expressed lncRNAs and mRNAs between the BoNTA treated group and control group by analyzing gene expression profiles. The number of changed lncRNAs was greater than that of mRNAs. Although currently the precise roles of the changed lncRNAs in BoNTA treated HDFs are not clear, lncRNAs have been regarded as vital regulators of gene expression and have various biofunctions. There are a large number of evidences demonstrating that lncRNAs can regulate gene expression by forming RNA-protein, RNA-RNA, DNA-RNA, and protein-DNA interactions \[[@B18]\]. Although no direct relationship was found between the altered lncRNA and mRNA expressions, we are convinced that the clear changes of lncRNAs (RP11-517C16.2-001, FR271872, LOC283352, RP11-401E9.3, FGFR3P, and XXbac-BPG16N22.5) in HDFs are in response to BoNTA and are related to the changes of protein-coding RNAs. We suspected that the decrease of NOS2 indicated the regulation of cell proliferation process \[[@B19], [@B20]\]. The increase of FOS induced by BoNTA showed the regulation of proliferation, which is also involved in the cellular senescence process of HDFs \[[@B21]--[@B24]\]. BIRC5 has been reported to participate in modulation of diverse cellular processes such as proliferation, adhesion, apoptosis, migration and invasion during growth, development, repair, maintenance, and regression of a wide variety of mesenchymal tissues \[[@B25]--[@B28]\]. The downregulated BIRC5 induced by BoNTA indicated the decrease of apoptosis in HDFs. PLAC8 has been proved to regulate cell cycle and participate in the regulation of apoptosis and cell division \[[@B29]--[@B31]\].

GO database was applied to analyze the function of the differentially expressed genes. The results were divided into three sections: biological process (BP), cellular component (CC), and molecular function (MF). Besides the top ten of the number of differentially expressed genes and the significance analyzed by GO term demonstrated in [Figure 4](#fig4){ref-type="fig"}, the analysis showed that the differentially expressed genes were also involved in a variety of other biological functions, such as negative regulation of autophagy (GO: 0010507), positive regulation of collagen biosynthetic process (GO: 0032967), regulation of G1/S transition of mitotic cell cycle (GO: 2000045), and positive regulation of fibroblast proliferation (GO: 0048147). The analysis indicated that the lncRNAs can affect the function of HDFs by regulating the expression profiles of genes related to HDFs. KEGG analysis can provide some suggestive information about the potential relativity of the changed gene expression with the alterations of the pathways. The result of our study indicates several significant pathways related to a variety of functions, such as cell proliferation, cell cycle, apoptosis, and DNA replication. It had been reported that BoNTA can regulate the process of cell cycle and DNA replication by other researchers. For example, G. Karsenty et al. reported in their study that BoNTA obviously reduced LNCaP cell proliferation and increased apoptosis in a dose-dependent manner \[[@B32]\]. Park et al. found that BoNTA upregulates the expression of cell cycle related genes such as RhoA, Rac1, and Cdc42 in a dose-dependent manner \[[@B33]\]. Our prediction results accord with the functional analysis of BoNTA obtained from other investigations.

QRT-PCR was applied to verify the result of microarray analysis. We learned from other studies that BoNTA can regulate cell proliferation and collagen synthesis; the mechanisms may play important roles in skin rejuvenation effects of BoNTA \[[@B32]--[@B34]\]. The RNAs chosen for qRT-PCR confirmation meet at least one of two following criteria: 1: the RNAs being at least 2-fold differently expressed in BoNTA treated groups in comparison with the control group according to the data analysis; 2: the RNAs that had been proved in other studies to have a relationship with biological functions such as cell proliferation and collagen synthesis. The qRT-PCR confirmation results of six lncRNAs (RP11-517C16.2-001, FR271872, LOC283352, RP11-401E9.3, FGFR3P, and XXbac-BPG16N22.5) and mRNAs (NOS2, C13orf15, FOS, FCN2, SPINT1, PLAC8, BIRC5, and COL19A1) were consistent with the microarray data which confirmed the reliability of our microarray analysis.

Next, we applied qRT-PCR to further investigate the expression changes of COL19A1 and FGFR3P after BoNTA treatment at different dosages and culture times. COL19A1, as one member of the fibril-associated collagens with interrupted triple helices (FACIT) group, is thought to act as a cross-bridge between extracellular matrix molecules (ECM) and is involved in the formation of the well-known striated fibrils \[[@B35]\]. Bioinformatic analysis reveals that FGFR3P which is located on chromosome 6 is defined as the pseudogene of Fibroblast Growth Factor Receptor 3 (FGFR3), noncoding RNA. FGFR3 is one member of FGFR family and had been reported to participate in the regulation of cell proliferation, apoptosis, migration, and angiogenesis in many cells including HDFs \[[@B36]--[@B39]\]. Although pseudogenes have been considered as the remnants of functional genes which have no coding ability over a long period of time, evergrowing number of studies have proved that some pseudogenes have diverse functions, including serving as miRNA decoys, functioning as antisense transcripts, encoding short peptides, and producing siRNAs or proteins \[[@B40]--[@B43]\]. Our results showed that downregulating effect of BoNTA on the expression of FGFR3P was time-related. Meanwhile, the dosage of BoNTA at a range from 2.5 U/10^6^ cells to 7.5 U/10^6^ cells increased the expression of FGFR3P and COL19A1 in HDFs as well. We speculated significant change of expression of these RNAs in a time-dependent manner after BoNTA treatment which may be of some clinical significance. Zhu et al. conducted one clinical experiment and found that topical application of BoNTA could enhance the rejuvenation effect of fractional CO~2~ laser; they also found that best results of skin detection were in the last observation point at 3 months after treatment \[[@B34]\]. Zhu et al. also performed another clinical study and found that intradermal BoNTA injection showed its best rejuvenation results in the last observation point at 12 weeks after treatment as well \[[@B44]\]. The results of the previous clinical investigations showed that BoNTA had a persistent promoting effect of collagen synthesis with the extending of time. Taking these into consideration, we speculate that BoNTA have the antiaging effect not only by relaxing in muscle fiber, but also by promoting activity of HDFs directly. The underlying mechanisms still need further studies.

In conclusion, for the first time, our current study identified the changes of expression profiles of lncRNAs in BoNTA treated HDFs and found that BoNTA dynamically regulated the expression of COL19A1 and FGFR3P in HDFs, indicating the potential role of several lncRNAs in BoNTA treated HDFs. Therefore, further explorations are warranted to discover the mechanisms behind the dynamic changes BoNTA induced on COL19A1 and FGFR3P and the findings obtained in this study should lay foundations for further studies into the potential roles of these altered lncRNAs in BoNTA treated HDFs.
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![Heat maps presentation of the expression profiling of mRNAs (a) and lncRNAs (b) in different groups of HDFs. Red and blue represent high and low relative expressions, respectively. Control indicates the normal HDFs and BoNTA indicates the HDFs treated by BoNTA (5 U/10^6^ cells 48 h).](BMRI2017-2957941.001){#fig1}

![The differential expression level of long noncoding RNAs (lncRNAs) between control and BoNTA (5 U/10^6^ cells 48 h) treated groups was validated by qRT-PCR. Six lncRNAs (RP11-517C16.2-001, FR271872, LOC283352, RP11-401E9.3, FGFR3P, and XXbac-BPG16N22.5) were studied using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an internal control. The heights of the columns in the chart represent the fold changes. Data are the mean ± SEM (*n* = 6). *p* \< 0.05 was considered to indicate a statistically significant difference compared with control HDFs. ^*∗*^*p* \< 0.05 and ^*∗∗*^*p* \< 0.01.](BMRI2017-2957941.002){#fig2}

![The differential expression levels of message RNAs (mRNAs) between control and BoNTA (5 U/10^6^ cells 48 h) treated groups of microarray results were validated by qRT-PCR. Nine mRNAs (FCN2, SPINT1, PLAC, BIRC5, E2F1, COL19A1, FOS, NOS2, and C13orf15) were studied using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an internal control. The heights of the columns in the chart represent the fold changes. Data are the mean ± SEM (*n* = 6). *p* \< 0.05 was considered to indicate a statistically significant difference compared with control HDFs. ^*∗*^*p* \< 0.05, ^*∗∗*^*p* \< 0.01, and ^*∗∗∗*^*p* \< 0.001.](BMRI2017-2957941.003){#fig3}

![Bioinformatic analysis of the differentially expressed genes. The*p* value denotes the significance of GO terms enrichment in the differentially expressed genes. The lower the*p* value, the more significant the GO term (*p* value ≤ 0.05 is recommended). We can choose the target genes for further study based on the combination of the analysis provided by GO and the biologic significance.](BMRI2017-2957941.004){#fig4}

![Pathway analysis of the differentially expressed genes. Fisher\'s exact test was used to select the main pathway, and the significance threshold was defined with*p* value. The lower the*p* value, the more significant the pathway (*p* value ≤0.05 is recommended). We can get some information about the possibility between the differentially expressed genes and the change of cellular pathways.](BMRI2017-2957941.005){#fig5}

![The regulation of BoNTA on the expression of FGFR3P and COL19A1 in HDFs. The expressions of FGFR3P and COL19A1 in HDFs different dosage of BoNTA were measured using qRT-PCR. The heights of the columns in the chart represent the fold changes. Data are the mean ± SEM (*n* = 6). *p* \< 0.05 was considered to indicate a statistically significant difference compared with control HDFs. ^*∗*^*p* \< 0.05 and ^*∗∗*^*p* \< 0.01.](BMRI2017-2957941.006){#fig6}

###### 

Primer sequences for long noncoding RNAs and protein-coding RNAs.

  Gene name                                                   Primer sequences
  ----------------------------------------------------------- -------------------------------------------------------
  RP11-517C16.2-001                                           Forward primer: TTTGTCAACGGGCTCTACCC
  Reverse primer: TTTGTCAACGGGCTCTACCC                        
                                                              
  FR271872                                                    Forward primer: CACCTCCTTCCCTGGACTAGA
  Reverse primer: CACCTCCTTCCCTGGACTAGA                       
                                                              
  LOC283352                                                   Forward primer: AAGGGTTTATGTGCTCGGAGG
  Reverse primer: CTGGCTGAGGAGTCTCACTT                        
                                                              
  RP11-401E9.3                                                Forward primer: CCAGTCATGCCCATCCAGAA
  Reverse primer: CCATGCAGCAACTAGCAAAGG                       
                                                              
  FGFR3P                                                      Forward primer: ATGGAAGGCTGCTTCATGCT
  Reverse primer: GTTTCAAGACCTCAGCGGGA                        
                                                              
  XXbac-BPG16N22.5                                            Forward primer: AGACTCAAGGGGACCAGACC
  Reverse primer: CTGCAGGCAGGTGTATCTCA                        
                                                              
  COL19A1                                                     Forward primer: TCGAGTACGAAGAAACGCCAA
  Reverse primer: TGCCACTGACGATCAAACAAA                       
                                                              
  NOS2                                                        Forward primer: ACATCGACCCGTCCACAGTAT
  Reverse primer: CAGAGGGGTAGGCTTGTCTC                        
                                                              
  C13orf15                                                    Forward primer: CTGAATTCTCCAACAGACT
  Reverse primer: ATGGGAAAGCTTACTGCT                          
                                                              
  E2F1                                                        Forward primer: AGCTGGACCACCTGATGAAT
  Reverse primer: GAGGGGCTTTGATCACCATA                        
                                                              
  SPINT1                                                      Forward primer: AGACTACTGCCTCGCATCCAA
  Reverse primer: CAAGCAGCCTCCATAAACGAA                       
                                                              
  FOS                                                         Forward primer: TGACAGATACACTCCAAGCGG
  Reverse primer: GGGAAGCCAAGGTCATCG                          
                                                              
  FCN2                                                        Forward primer: GTAAAACGACGGCCAGTTATGGCCCTGCTTCTTCCTC
  Reverse primer: TTCCAGAGTGTGTTCTCCCAC                       
                                                              
  PLAC8                                                       Forward primer: CCTCTACACTGCCTCAGCATC
  Reverse primer: GTAAAACGACGGCCAGTTTCTACACAATAAGGGAGGAATGG   
                                                              
  BIRC5                                                       Forward primer: AGGACCACCGCATCTCTACAT
  Reverse primer: AAGTCTGGCTCGTTCTCAGTG                       

###### 

Differentially expressed long noncoding RNAs in HDFs (fold change \> 5).

  Probe name               Gene symbol         Expression   Chromosome      Strand   Start       End         Fold change
  ------------------------ ------------------- ------------ --------------- -------- ----------- ----------- -------------
  CUST_18266               RP11-262H14.3-005   Up           Chr9            −        66513657    66553531    18.14
  CUST_28663               linc-TCTE3-3        Up           Chr6            −        170470884   170475667   9.33
  CUST_73981               linc-GRAMD3-2       Up           Chr5            \+       124372380   124486527   8.12
  CUST_25057               Z83001.1-003        Up           Chr11           −        31710730    31789373    7.07
  CUST_54220               RP11-517C16.2-001   Up           Chr16           −        84492865    84500967    6.13
  CUST_77914_PI429545380   RP11-444D13.1-001   Up           chr1            −        183723553   183724072   5.70
  CUST_42824_PI429545402   RPS2P41             Up           chr12           −        112317141   112318053   5.63
  CUST_24581_PI429545380   FR271872            Up           chr1            \+       40364066    40364332    5.55
  CUST_27762_PI429545402   KLRD1               Up           chr12           \+       10378664    10467608    5.45
  CUST_42463_PI429545376   linc-SCGB1D4-2      Up           chr11           −        62178649    62179162    5.35
  CUST_83283_PI429545395   RSPH10B             Up           chr7            −        5995734     6002990     5.34
  CUST_63264_PI429545410   LOC283352           Up           chr12           \+       129594234   129597843   5.34
  CUST_70508_PI429545399   RP11-401E9.3        Up           chr10           −        7875580     7875920     5.05
  CUST_70526               MTHFD1              Down         Chr14           \+       64924714    64926721    −25.69
  CUST_86832               AC010136.2-001      Down         Chr2            \+       218843430   218857338   −8.43
  CUST_75452               PNKP                Down         Chr19           −        50369397    50370818    −8.04
  CUST_89880               STPG1               Down         Chr1            −        24717747    24742643    −7.77
  CUST_45703               RP11-643A5.2-002    Down         Chr15           −        54239821    54267147    −6.66
  CUST_15063               FGFR3P              Down         chr6_cox_hap2   \+       2857852     2858455     −6.52
  CUST_29613               linc-HOXA11         Down         Chr7            −        27226865    27232305    −6.25
  CUST_33771               FR081392            Down         Chr6            \+       161943497   161943737   −6.21
  CUST_75093               CTA-292E10.6-001    Down         Chr22           \+       29196671    29244547    −6.04
  CUST_90031_PI429545395   RP11-73B2.7         Down         chr7            −        63398282    63398887    −5.63
  CUST_81910_PI429545380   AC007131.2-003      Down         chr2            −        59465851    59476702    −5.5
  CUST_92526_PI429545402   ZFAND6              Down         chr15           \+       80364932    80413144    −5.2
  CUST_62442_PI429545395   XXbac-BPG16N22.5    Down         chr6            \+       31483755    31483988    −5.14
  CUST_19370_PI429545380   FR316649            Down         chr3            \+       188550879   188551155   −5.07

###### 

Differentially expressed protein-coding RNAs in HDFs (fold change \> 3).

  Probe name      Gene symbol   Expression   Chromosome   Strand   Start        End         Fold change
  --------------- ------------- ------------ ------------ -------- ------------ ----------- -------------
  A_33_P3367396   FAM177B       Up           Chr1         \+       222923479    222923538   30.05
  A_33_P3400699   SLC26A5       Up           Chr9         −        10 2993259   102993200   5.16
  A_23_P502464    NOS2          Up           Chr17        −        26083921     26083862    4.21
  A_33_P3423270   TMEM40        Up           Chr3         −        12775584     12775525    4.08
  A_24_P183128    PLAC8         Up           Chr4         −        84015842     84012077    4.03
  A_23_P135226    OR1N2         Up           Chr9         \+       125316281    125316340   3.91
  A_23_P153616    MADCAM1       Up           Chr19        \+       505192       505251      3.89
  A_23_P49060     SPINT1        Up           Chr15        \+       41149316     41149375    3.58
  A_24_P10137     C13orf15      Up           Chr13        \+       42042937     42044635    3.42
  A_24_P630490    DFNB59        Up           Chr2         \+       179325165    179325759   3.38
  A_23_P106194    FOS           Up           Chr14        \+       75748214     75748273    3.05
  A_23_P313588    TMPRSS6       Up           Chr22        −        37480125     37480066    3.04
  A_23_P134085    CNKSR3        Down         Chr6         −        154726608    154726549   −14.99
  A_24_P323598    ESCO2         Down         Chr8         \+       27662101     27662160    −5.44
  A_23_P216756    FCN2          Down         Chr9         \+       137779164    137779223   −4.27
  A_24_P225616    RRM2          Down         Chr2         \+       10270487     10270546    −4.19
  A_23_P15844     BRIP1         Down         Chr17        −        59760967     59760908    −4.04
  A_23_P126212    CLSPN         Down         Chr1         −        36204176     36204117    −3.85
  A_33_P3807062   HJURP         Down         Chr2         −        234746088    234746029   −3.84
  A_23_P100127    CASC5         Down         Chr15        \+       40917525     40917584    −3.81
  A_33_P3257678   HIST2H3A      Down         Chr1         \+       149824626    149824685   −3.79
  A_33_P3326210   ESCO2         Down         Chr8         \+       27660830     27660889    −3.72
  A_23_P8452      LFNG          Down         Chr7         \+       2567971      2568030     −3.70
  A_23_P51085     SPC25         Down         Chr2         −        169728015    169727956   −3.61
  A_23_P130182    AURKB         Down         Chr17        −        8110917      8110655     −3.59
  A_23_P254733    MLF1IP        Down         Chr4         −        185616396    185616337   −3.49
  A_23_P133956    KIFC1         Down         Chr6         \+       33374428     33374621    −3.48
  A_24_P214231    STIL          Down         Chr1         −        47716850     47716791    −3.45
  A_23_P131330    LRRTM1        Down         Chr2         −        80529291     80529232    −3.45
  A_32_P96719     HIST1H2AL     Down         Chr6         −        27833502     27833561    −3.27
  A_23_P363174    GTSE1         Down         Chr22        \+       46725391     46725450    −3.23
  A_23_P118246    GINS2         Down         Chr16        −        85711713     85711654    −3.20
  A_24_P322354    SKA1          Down         Chr18        \+       47919899     47919958    −3.14
  A_23_P118815    BIRC5         Down         Chr17        \+       76220720     76220779    −3.08
  A_24_P413884    CENPA         Down         Chr2         \+       27016914     27016973    −3.06
  A_24_P314571    SPC24         Down         Chr19        −        11257053     11256994    −3.05
  A_23_P99292     RAD51AP1      Down         Chr12        \+       4668182      4668241     −3.01
  A_23_P80032     E2F1          Down         Chr20        −        32264048     32263989    −3.01

[^1]: Academic Editor: Hai-Feng Pan
